Was glaubt ihr, wie geht es mit Tetraphase weiter?
Beste Grüsse,
Andreas
Beste Grüsse,
Andreas
Top-News
Wie geht es mit Tetraphase weiter?
Beiträge: 70
Zugriffe: 21.572 / Heute: 2
Zugriffe: 21.572 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +72,94%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +55,51%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,10%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +37,57%
und dann einsteigen. In ein paar Wochen kann man die ersten Stücke kaufen. I.d.R. steigen Bio's nach Abstürzen immer.
Aber jetzt erstmal Seitenlinie!
Aber jetzt erstmal Seitenlinie!
Boerse ist reine Psychologie. Nicht mehr und nicht weniger.
eine gemütliche Erholung:
Nach 8,31 USD Tief
die 9 USD wieder,
die 10 USD wieder,
Wer weiß, ggf. heute noch
die 11 USD wieder
usw.?
Nach 8,31 USD Tief
die 9 USD wieder,
die 10 USD wieder,
Wer weiß, ggf. heute noch
die 11 USD wieder
usw.?
streng durch die 11 USD.
Da bin ich nun gespannt (auf einen Freitag, bei negativem Umfeld).
Da bin ich nun gespannt (auf einen Freitag, bei negativem Umfeld).
sleekmoney.com/...verage-price-target-from-brokerages/1053272/
...mal sehen, was die Amis heute Mittag anstellen :)
Tetraphase floppt in Phase 3 Studie
endpts.com/...-antibiotic-fails-in-a-repeat-setback-for-utis/
endpts.com/...-antibiotic-fails-in-a-repeat-setback-for-utis/
www.finanzen.net/analyse/...-Stifel_Nicolaus__Co__Inc__636167
www.finanzen.net/analyse/...ls_Buy-H_C_Wainwright__Co__636148
Die alten Kursziele der Analysten kannst du getrost vergessen. Ich hab mir mal den Cashbestand, den Cashburn und die MK angeschaut und pack Tetraphase erstmal auf die Watchlist.
www.fiercebiotech.com/biotech/...isses-endpoints-phase-3-flop
www.fiercebiotech.com/biotech/...isses-endpoints-phase-3-flop
globenewswire.com/news-release/2018/02/20/...ne-in-China.html
......"Under the terms of the agreement, Tetraphase will receive an initial upfront payment of $7.0million and may receive clinical and regulatory milestones of up to $16.5 million as well as annual sales milestones of up to $20.0 million....."
www.analystratings.com/articles/...-stock-is-going-to-recover/
mir sehr gut, ir.tphase.com/news-releases/...s-second-quarter-2018-financial
"...In the second quarter of 2018, we moved closer to achieving our goal to bring XeravaTM (eravacycline) to market on a global level as an important new antibiotic for patients with serious, often life-threating, complicated intra-abdominal infections (cIAI),” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We recently announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Xerava in cIAI, and we expect a final decision on marketing authorization from the European Commission (EC) later this year. In the U.S., we are eagerly looking forward to a decision on our PDUFA (Prescription Drug User Fee Act) date of August 28, 2018 and we are actively preparing for the potential commercial launch of Xerava in the fourth quarter...."
Der letzte Satz wird hier wohl entscheidend.
"...As of June 30, 2018, Tetraphase had cash and cash equivalents of $111.2 million and 52.9 million shares outstanding. The Company expects that its cash and cash equivalents, as well as expected revenue from its U.S. government awards, will be sufficient to fund operations through the third quarter of 2019..."
Cash Seite schaut auch gut aus.
"...In the second quarter of 2018, we moved closer to achieving our goal to bring XeravaTM (eravacycline) to market on a global level as an important new antibiotic for patients with serious, often life-threating, complicated intra-abdominal infections (cIAI),” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We recently announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Xerava in cIAI, and we expect a final decision on marketing authorization from the European Commission (EC) later this year. In the U.S., we are eagerly looking forward to a decision on our PDUFA (Prescription Drug User Fee Act) date of August 28, 2018 and we are actively preparing for the potential commercial launch of Xerava in the fourth quarter...."
Der letzte Satz wird hier wohl entscheidend.
"...As of June 30, 2018, Tetraphase had cash and cash equivalents of $111.2 million and 52.9 million shares outstanding. The Company expects that its cash and cash equivalents, as well as expected revenue from its U.S. government awards, will be sufficient to fund operations through the third quarter of 2019..."
Cash Seite schaut auch gut aus.
Die Aktie stieg ca. 9%. Morgen wird die approval verkündet und TTPH geht durch die Decke.
nur m.M
nur m.M
..bereits gestern verkündet. Heute: sell on good news - oder Explosion?
FDA erteilt Zulassung für Xerava
www.pharmaceutical-business-review.com/...dominal-infections/
Commercial Launch of Xerava in U.S.
ir.tphase.com/news-releases/...ces-commercial-launch-xeravatm
Tetraphase meldet Ergebnisse für Q3/18
ir.tphase.com/news-releases/...s-third-quarter-2018-financial
- 97 Mio. $ Cash
- MK 102 Mio. $
|
Neueste Beiträge aus dem Tetraphase Pharmaceuticals Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 69 | Wie geht es mit Tetraphase weiter? | Arrko | Vassago | 30.07.20 17:59 |
